GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (FRA:ANW) » Definitions » EPS (Diluted)

Immuron (FRA:ANW) EPS (Diluted) : €-0.01 (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Immuron EPS (Diluted)?

Immuron's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was €-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.01.

Immuron's EPS (Basic) for the six months ended in Dec. 2023 was €-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.01.

Immuron's EPS without NRI for the six months ended in Dec. 2023 was €-0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.01.

During the past 3 years, the average EPS without NRIGrowth Rate was 2.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Immuron's highest 3-Year average EPS without NRI Growth Rate was 34.30% per year. The lowest was -16.10% per year. And the median was 18.60% per year.


Immuron EPS (Diluted) Historical Data

The historical data trend for Immuron's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron EPS (Diluted) Chart

Immuron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only -0.02 -0.01 -0.02 -0.01 -0.01

Immuron Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 - -0.01 -0.01 -0.01

Competitive Comparison of Immuron's EPS (Diluted)

For the Biotechnology subindustry, Immuron's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immuron's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuron's PE Ratio distribution charts can be found below:

* The bar in red indicates where Immuron's PE Ratio falls into.



Immuron EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Immuron's Diluted EPS for the fiscal year that ended in Jun. 2023 is calculated as

Diluted EPS (A: Jun. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.346-0)/227.798
=-0.01

Immuron's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.272-0)/227.798
=-0.01

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immuron  (FRA:ANW) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Immuron EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Immuron's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuron (FRA:ANW) Business Description

Traded in Other Exchanges
Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (FRA:ANW) Headlines

No Headlines